| abstract |
The present disclosure provides an improved genomic editing composition and method of editing the PD-1 gene. The present disclosure further provides genomic edited cells for the prevention, treatment or amelioration of at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease or immune deficiency. |